Akebia Therapeutics, Inc. (AKBA) Form 10-Q — Aug 5, 2026
Akebia Therapeutics reported Q2 2026 total revenue of $49.1 million, down 21% year over year, and swung to a net loss of $8.9 million ($0.03 per share) from net income of $0.2 million a year ago. The decline was driven by Auryxia, which fell 46% YoY to $25.5 million following its March 2025 U.S. loss of exclusivity and Teva's March 2026 generic launch. Vafseo was the offsetting bright spot, with U.S.
Key figures
- Revenue
- 49128000
- Total Debt
- 49563000
- Revenue Yoy
- -21.4%
- Total Assets
- 349658000
- Cash Position
- 155548000
- Shares Outstanding
- 277106245
- H1 2026 revenue
- 102672000
- Total liabilities
- 324640000
- Vafseo q2 revenue
- 21302000
- Atm shares sold h1
- 3138107
- Auryxia q2 revenue
- 25463000
- Term loan maturity
- January 29, 2028
- Stockholders equity
- 25018000
- Atm program capacity
- 75000000
- Atm gross proceeds h1
- 3400000
- Q2 2025 total revenue
- 62472000
- Inventory write down h1
- 4943000
- Restructuring charge q2
- 1945000
- Future royalty liability
- 51484000
- Term loan interest rate pct
- 11
- Settlement royalty liability
- 70472000
- Term loan principal due 2027
- 50558000
- Working capital fund liability
- 31887000
- Wuxi sta purchase commitment through 2027
- 69200000
Price after filing
1 day: 0.0%7 days: -32.3%30 days: -25.5%
Close on the filing date to close N calendar days later (from $1.32). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.